Eli Lilly lifts 2026 revenue forecast to $87 billion on incretin sales
Mounjaro sales rose 91% to $9.94 billion in the quarter while the new oral obesity pill Foundayo brought in $98 million, missing estimates.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: BNN Bloomberg
The wire
- 01Lilly raised full-year revenue guidance to $85-87 billion from $82-85 billion and posted adjusted EPS of $8.38 for the quarter ended June 30, beating the $6.01 consensus.
- 02Mounjaro and Zepbound together made up 64.7% of revenue, signalling continued incretin demand despite pricing pressure and Novo's oral Wegovy launch in the US.
- 03Foundayo's $98 million debut quarter fell short of the $105.6 million expected, and Lilly trimmed the top end of its profit forecast on quarterly charges.
From the source
Read at bnnbloomberg.caEli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth
Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5 per cent in premarket trading.